Roche starts Phase II trial of RG6434 in early symptomatic Alzheimer's disease
Roche is initiating TARBELA-AD, a Phase II trial of oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease. The company also announced upcoming presentations on trontinemab, a Phase III trial and blood tests at CTAD in November 2026.
1. Alzheimer's trial plans
Roche is initiating TARBELA-AD, a Phase II trial testing oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease, targeting neuroinflammation. The company said updated trontinemab results and presentations on Phase III PrevenTRON and Elecsys pTau217 and pTau181 blood tests are scheduled for CTAD in Boston, November 16-19, 2026.
